Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of CA$4.96M rose 32.1% year over year, ahead of the +22.5% change in trailing-twelve-month research & development. Sequentially, it rose 80.9% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.1% holds above the trailing-twelve-month pace of +22.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$4.96M+80.9% QoQ
Last fiscal yearDec 2025
CA$14.02M+0.0% YoY
LTMMar 2026
CA$15.22M+22.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.1%——
1 year+0.0%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
14.02M CAD
Year-over-year change
+0.0%
4-year CAGR
+13.0%

Research & Development vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.5% is the 3rd highest of 10, against a peer median of -11.4%.
  • Over three fiscal years its annual growth of +0.1% compares with a peer median of -13.3%.
CRDL Competitors
Research & Development for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTBConnect Biopharma Holdings LimitedFY2025$37.8M USD+29.2%-26.9%59059.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$32.3M USD-29.1%+37.8%—
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M USD+11.9%+8.6%—
HYPRHyperfine, Inc.LTM Mar 2026$16.26M USD-26.0%-14.7%106.1%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$15.22M CAD+22.5%+0.1%—
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M USD-11.4%-6.7%5814.3%
ASRTAssertio Holdings, Inc.LTM Mar 2026$1.71M USD-51.6%—1.7%
INCRInterCure Ltd.LTM Jun 2025₪386K ILS+10.0%-14.9%0.2%
Peer median (excluding CRDL) —-11.4%-13.3%2960.2%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.